terazosin Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
antihypertensive substances, prazosin derivatives 3584 63590-64-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • terazosin
  • terazosin hydrochloride
  • terazosin hydrochloride anhydrous
  • terazosine
  • terazosin hydrochloride hydrate
  • terazosin HCl
induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia
  • Molecular weight: 387.44
  • Formula: C19H25N5O4
  • CLOGP: 2.18
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 1
  • TPSA: 103.04
  • ALOGS: -2.41
  • ROTB: 4

Drug dosage:

DoseUnitRoute
5 mg O

Approvals:

DateAgencyCompanyOrphan
Aug. 7, 1987 FDA

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypotension 912.85 60.70 230 596 67170 4570996
Syncope 878.85 60.70 196 630 33199 4604967
Dizziness 706.53 60.70 205 621 99666 4538500
Orthostatic hypotension 444.09 60.70 86 740 6788 4631378
Fall 185.27 60.70 72 754 77974 4560192
Bradycardia 111.13 60.70 36 790 22533 4615633
Loss of consciousness 91.37 60.70 35 791 35647 4602519
Presyncope 73.16 60.70 20 806 6944 4631222
Asthenia 67.37 60.70 37 789 86126 4552040

Pharmacologic Action:

SourceCodeDescription
ATC G04CA03 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
Alpha-adrenoreceptor antagonists
MeSH PA D018663 Adrenergic Agents
MeSH PA D058668 Adrenergic alpha-1 Receptor Antagonists
FDA EPC N0000175553 alpha-Adrenergic Blocker
MeSH PA D000317 Adrenergic alpha-Antagonists
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:37890 alpha-adrenergic antagonist
MeSH PA D064804 Urological Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Benign prostatic hyperplasia indication 266569009
Priapism contraindication 6273006 DOID:9286
Orthostatic hypotension contraindication 28651003
Cataract surgery contraindication 110473004
Syncope contraindication 271594007
Intraoperative floppy iris syndrome contraindication 418801006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.22 Basic
pKa2 0.72 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-1A adrenergic receptor GPCR ANTAGONIST Ki 8.95 WOMBAT-PK CHEMBL
Alpha-1D adrenergic receptor GPCR ANTAGONIST Ki 9.20 WOMBAT-PK CHEMBL
Alpha-1B adrenergic receptor GPCR ANTAGONIST Ki 9.08 WOMBAT-PK CHEMBL
Alpha-2C adrenergic receptor GPCR Ki 6.88 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 6.93 WOMBAT-PK
Alpha-2A adrenergic receptor GPCR Ki 6.26 WOMBAT-PK
Solute carrier family 22 member 1 Transporter IC50 4.63 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4.75 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 5.45 PDSP
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme WOMBAT-PK
Alpha-1B adrenergic receptor GPCR Ki 9.16 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 7.59 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 9.09 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 8.11 CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 9 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 8.72 CHEMBL

External reference:

IDSource
4019940 VUID
N0000179262 NUI
C0076107 UMLSCUI
D00610 KEGG_DRUG
129484001 SNOMEDCT_US
4019940 VANDF
37798 RXNORM
44696 MMSL
387068008 SNOMEDCT_US
d00386 MMSL
004492 NDDF
8L5014XET7 UNII
4843 INN_ID
63074-08-8 SECONDARY_CAS_RN
CHEMBL611 ChEMBL_ID
TZN PDB_CHEM_ID
DB01162 DRUGBANK_ID
CHEBI:9445 CHEBI
CHEMBL1201091 ChEMBL_ID
CHEMBL1256665 ChEMBL_ID
CHEMBL3989562 ChEMBL_ID
5401 PUBCHEM_CID
7302 IUPHAR_LIGAND_ID
C041226 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Terazosin Hydrochloride Anhydrous HUMAN PRESCRIPTION DRUG LABEL 1 0378-1570 CAPSULE 10 mg ORAL ANDA 12 sections
Terazosin Hydrochloride Anhydrous HUMAN PRESCRIPTION DRUG LABEL 1 0378-2260 CAPSULE 1 mg ORAL ANDA 12 sections
Terazosin Hydrochloride Anhydrous HUMAN PRESCRIPTION DRUG LABEL 1 0378-2264 CAPSULE 2 mg ORAL ANDA 12 sections
Terazosin Hydrochloride Anhydrous HUMAN PRESCRIPTION DRUG LABEL 1 0378-2268 CAPSULE 5 mg ORAL ANDA 12 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-1337 CAPSULE 1 mg ORAL ANDA 14 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 0615-1338 CAPSULE 2 mg ORAL ANDA 12 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 0615-1339 CAPSULE 5 mg ORAL ANDA 12 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2051 CAPSULE 1 mg ORAL ANDA 12 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2052 CAPSULE 2 mg ORAL ANDA 12 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2053 CAPSULE 5 mg ORAL ANDA 12 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2054 CAPSULE 10 mg ORAL ANDA 12 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 10544-289 CAPSULE 10 mg ORAL ANDA 12 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-812 CAPSULE 2 mg ORAL ANDA 13 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-813 CAPSULE 5 mg ORAL ANDA 13 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 33261-211 CAPSULE 1 mg ORAL ANDA 12 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 33261-212 CAPSULE 2 mg ORAL ANDA 12 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 33261-870 CAPSULE 10 mg ORAL ANDA 12 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 42291-820 CAPSULE 1 mg ORAL ANDA 11 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 42291-821 CAPSULE 2 mg ORAL ANDA 11 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 42291-822 CAPSULE 5 mg ORAL ANDA 11 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 42291-823 CAPSULE 10 mg ORAL ANDA 11 sections
TERAZOSIN HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 42549-666 CAPSULE 5 mg ORAL ANDA 12 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 49999-227 CAPSULE 5 mg ORAL ANDA 12 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-0659 CAPSULE 10 mg ORAL ANDA 12 sections
Terazosin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50090-1943 CAPSULE 5 mg ORAL ANDA 12 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 50090-2371 CAPSULE 10 mg ORAL ANDA 12 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 50268-764 CAPSULE 1 mg ORAL ANDA 11 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 50268-765 CAPSULE 2 mg ORAL ANDA 11 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 50268-766 CAPSULE 5 mg ORAL ANDA 11 sections
Terazosin HUMAN PRESCRIPTION DRUG LABEL 1 50268-767 CAPSULE 10 mg ORAL ANDA 11 sections